Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telatinib + CapOx in First-Line Advanced Gastric Cancer
NCT03817411Phase 2Unknown
- Sponsor
- EOC Pharma
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Telatinib + CapOx with Placebo + CapOx (2 arms). Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
telatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03817411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817411.